Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 7Gynecologic 3Genitourinary 2Gastrointestinal 2Tumor-Agnostic 1Other solid neoplasm 1Head & Neck 1Endocrine 1CNS 1Breast 1

Conditions

Small Cell Lung Carcinoma 1Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

Radiotherapy 63Temozolomide 59Magnetic Resonance Spectroscopy 46Carboplatin 40Cyclophosphamide 39Vincristine 35Specimen Handling 28Etoposide 26Cisplatin 26Radiation 22Chemotherapy, Adjuvant 22Filgrastim 20Bevacizumab 20Doxorubicin 18Peripheral Blood Stem Cell Transplantation 17Biopsy 17Vorinostat 16Surgical Procedures, Operative 14Melphalan 13Immunoglobulin G 13Disulfides 13Radiotherapy, Conformal 12Isotretinoin 12Erlotinib Hydrochloride 12X-Rays 11Nivolumab 11Irinotecan 11Carmustine 11aldesleukin 10Topotecan 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × berzosertib × CNS × Clear all
NCT02589522 2026-04-29

Testing the Safety of M6620 (VX-970) When Given With Standard Whole Brain Radiation Therapy for the Treatment of Brain Metastases From Non-small Cell Lung Cancer, Small Cell Lung Cancer, or Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
15 enrolled 10 charts
CNSThoracic

Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡